[HTML][HTML] Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic …
Immune checkpoint therapies (ICT) can reinvigorate the effector functions of anti-tumour T
cells, improving cancer patient outcomes. Anti-tumour T cells are initially formed during their …
cells, improving cancer patient outcomes. Anti-tumour T cells are initially formed during their …
Determinants of resistance and response to melanoma therapy
BM Robertson, ME Fane, AT Weeraratna… - Nature Cancer, 2024 - nature.com
Metastatic melanoma is among the most enigmatic advanced cancers to clinically manage
despite immense progress in the way of available therapeutic options and historic …
despite immense progress in the way of available therapeutic options and historic …
[HTML][HTML] TIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicity
M Langguth, E Maranou, SA Koskela, O Elenius… - Genes & …, 2024 - nature.com
Immune checkpoint therapies (ICT) for advanced solid tumors mark a new milestone in
cancer therapy. Yet their efficacy is often limited by poor immunogenicity, attributed to …
cancer therapy. Yet their efficacy is often limited by poor immunogenicity, attributed to …
Dysfunctional states of unconventional T-cell subsets in cancer
EN Katsnelson, A Spengler, J Domenico… - Journal of Leukocyte …, 2024 - academic.oup.com
Unconventional T cells represent a promising therapeutic agent to overcome the current
limitations of immunotherapies due to their universal T-cell receptors, ability to respond …
limitations of immunotherapies due to their universal T-cell receptors, ability to respond …